<!DOCTYPE html>
<html lang="en" dir="ltr">

<head>
  <title>IgAN Patient Case - Explore Sarah's Journey</title>
  <meta name="description" content="Explore Sarah’s journey with IgAN, from diagnosis to disease progression. Learn how this autoimmune kidney disease can impact her quality of life">
  {{> ../templates/header }}
  <link href="../styles.bundle.css" rel="stylesheet" type="text/css">
</head>

<body>
  <!-- Google Tag Manager (noscript) -->
  <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-WZLFQZR3" height="0" width="0"
      style="display:none;visibility:hidden"></iframe></noscript>
  <!-- End Google Tag Manager (noscript) -->
  <main class="wrapper" data-page-id="pat-profile-sarah" data-path-level="2">

    {{> ../templates/nav }}
    {{> ../templates/interstitial }}

    <div class="progress-dots-container"></div>

    {{> ../templates/mestc-score-modal }}

    <img id="scroll-arrow" class="update-path" src="./assets/images/scroll-arrow.svg" alt="Scroll arrow down" />

    <div id="sarah-bio-tray" class="mobile-bio-tray">
      <div id="tray-close">
        <p>活检时的基线评估</p>
        <img src="./assets/images/back-arrow.svg" class="update-path arrow" alt="Back arrow"/>
      </div>

      <p class="name">莎拉，25岁</p>

      {{> ../templates/sarah-bio }}

      <div class="extra-section">
        <p class="extra-footnote">*图片经 Renal Fellow Network授权使用，来源：Gallan A. Kidney biopsy of the Month. 2019年7月29日在线发表，可在此处查看: Kidney Biopsy of the Month: IgA Nephropathy - Renal Fellow Network/。</p>
        <p class="extra-footnote">ACE：血管紧张素转换酶；ARB：血管紧张素II受体阻滞剂；eGFR：估算肾小球滤过率；HPF：高倍视野；MEST-C：系膜细胞增生（M）、毛细血管内皮细胞增生（E）、节段性硬化（S）、肾小管萎缩和间质纤维化（T）、新月体（C）；PAS：过碘酸-希夫（染色法）；RBC：红细胞；UPCR，尿蛋白肌酐比值。</p>
      </div>
    </div>

    <!-- //////////////////// SECTION 1 ///////////////////// -->

    <section id="section-1" class="" data-section-id="1" data-section-name="Sarah Patient Information" data-dot-label="走近莎拉">

      <div class="two-column">

        <div id="left-bio">
          <img src="./assets/images/profiles/sarah-profile.png" class="update-path bio-pic" alt="">
          
          {{> ../templates/sarah-bio }}
        </div>

        <div class="right-side">
          <img src="./assets/images/profiles/sarah-profile.png" class="update-path bio-pic conditional-render" alt="">
          <p class="name conditional-render">莎拉，25岁</p>

          <h1 class="sect-1-header">莎拉是一名 25 岁的美籍日裔女性，刚从法学院毕业。<br class="desktop-only">在初次检查前 6 个月，她就职于当地一家工作节奏很快的律所。</h1>

          <p class="bold">在上呼吸道感染后，过去 2 天里莎拉出现了深棕色尿液。<br class="desktop-only">目前莎拉未处于经期，且青少年时期有过类似情况。</p>

          <ul class="bullet-list">
            <li><span class="bullet">&bull;</span><span>体格检查无明显异常</span></li>
            <li><span class="bullet">&bull;</span><span>尿液分析显示RBC/HPF &gt;25 个&#65292;<br class="desktop-only">蛋白（2+）</span></li>
          </ul>

          <div class="divider"></div>

          <h4 class="purple">莎拉转诊至肾病科医生处进行后续检查：</h4>

          <div class="flex">
            <div class="workup">
              <img class="icon update-path" src="./assets/images/gauge-icon.svg" alt="" />
              <p>UPCR 2.1 g/g（约 24 h 尿蛋白<br class="desktop-only">排泄量 2.1 g/d）</p>
            </div>
            <div class="workup">
              <img class="icon update-path" src="./assets/images/kidneys-icon.svg" alt="" />
              <p>肾活检显示以 IgA 沉积为主&#65292;<br class="desktop-only">且伴随系膜细胞增生&#65292;<br class="desktop-only">莎拉由此确诊IgA肾病</p>
            </div>
          </div>

          <p class="direction bold align-center tablet-desktop-only">点击下方轮播图中的箭头，查看莎拉的基线特征</p>
        </div>

      </div>
    </section>

    <div class="temp-section mobile-only">
      <p class="direction bold align-center">滑动下方轮播图，查看莎拉的基线特征</p>
    </div>

    <!-- //////////////////// SECTION 2 ///////////////////// -->

    <section id="section-2" class="" data-section-id="2" data-section-name="Sarah Demographic and Information Carousel" data-dot-label="基线特征">

      <div class="owl-carousel">
        <div class="carousel-block" id="sarah-block-1">
          <h3 class="label">活检时年龄</h3>
          <h4 class="characteristic">25 岁</h4>

          <ul class="bullet-list">
            <li><span class="bullet">&bull;</span><span>IgA肾病主要在 20-40 岁的成年人中确诊<sup>1,2</sup></span></li>
            <li><span class="bullet">&bull;</span><span>临床表现和疾病进展会因患者确诊时的年龄不同而产生差异<sup>3</sup></span></li>
          </ul>

          <div class="footnotes">
            <p><span class="bold">参考文献: 1.</span> Caster DJ, et al. <em>Kidney Int Rep</em>. 2023;8(9):1792-1800.
              <span class="bold">2.</span> Lai KN, et al. <em>Nat Rev Dis Primers</em>. 2016;2:16001. <span
                class="bold">3.</span> Gutierrez E, et al. <em>Nephrol Dial Transplant</em>. 2018;33:472-477.</p>
          </div>
        </div>

        <div class="carousel-block" id="sarah-block-2">
          <h3 class="label">种族</h3>
          <h4 class="characteristic">东亚人（日本人）</h4>

          <ul class="bullet-list">
            <li><span class="bullet">&bull;</span><span>IgA肾病的临床表现和疾病进展会因种族不同而产生较大差异<sup>1</sup></span></li>
            <li><span class="bullet">&bull;</span><span>亚裔人群疾病更快进展，疾病负担更重<sup>1</sup></span></li>
            <ul>
              <li><span class="bullet">&ndash;</span><span>东亚患者发展为ESKD的可能性是其他人群的4 倍</span>
              </li>
            </ul>
          </ul>

          <div class="footnotes">
            <p>ESKD：终末期肾病。</p>
            <p><span class="bold">参考文献: 1.</span> Yeo SC, et al. <em>Nephrology (Carlton)</em>. 2019;24(9):885-895.
            </p>
          </div>
        </div>

        <div class="carousel-block" id="sarah-block-3">
          <h3 class="label">活检时eGFR</h3>
          <h4 class="characteristic">70 mL/min/<br class="mobile-only"/>1.73 m<sup>2</sup></h4>

          <ul class="bullet-list">
            <li><span class="bullet">&bull;</span><span>莎拉活检时的eGFR表明，她正处于CKD2 期：肾脏已出现一定损伤，导致肾功能轻度下降</span></li>
            <li><span class="bullet">&bull;</span><span>eGFR下降是IgA肾病疾病进展已知的风险因素，且与CKD进展风险及死亡风险密切相关<sup>1</sup></span></li>
          </ul>

          <div class="footnotes">
            <p>CKD：慢性肾脏病；eGFR：估算肾小球滤过率。</p>
            <p><span class="bold">参考文献: 1.</span> Coresh J, et al. <em>JAMA</em>. 2014;311(24):2518-2531.</p>
          </div>
        </div>

        <div class="carousel-block" id="sarah-block-4">
          <h3 class="label">活检时血压</h3>
          <h4 class="characteristic">130/80 mm Hg</h4>

          <ul class="bullet-list">
            <li><span class="bullet">&bull;</span><span>莎拉活检时血压轻度升高</span></li>
            <li><span class="bullet">&bull;</span><span>诊断时，高血压可作为 IgA 肾病疾病进展的预测因素<sup>1</sup></span></li>
            <li><span class="bullet">&bull;</span><span>控制高血压可降低进展为肾衰竭的风险<sup>2</sup></span></li>
          </ul>

          <div class="footnotes">
            <p><span class="bold">参考文献：1.</span> Maixnerova D, et al. <em>J Nephrol</em>. 2016;29(4):535-541.
              <span class="bold">2.</span> KDIGO. <em>Kidney Int</em>. 2021;100:S1-S276.</p>
          </div>
        </div>

        <div class="carousel-block" id="sarah-block-5">
          <h3 class="label">活检时蛋白尿</h3>
          <h4 class="characteristic">2.1 g/d</h4>

          <ul class="bullet-list">
            <li><span class="bullet">&bull;</span><span>活检时莎拉的蛋白尿水平升高</span></li>
            <li><span class="bullet">&bull;</span><span>蛋白尿是公认的预后标志物，与长期肾脏结局相关，包括eGFR下降和ESKD进展<sup>1,2</sup></span></li>
            <li><span class="bullet">&bull;</span><span>蛋白尿减少与血清肌酐倍增、ESKD及死亡风险呈负相关<sup>2,3</sup></span></li>
          </ul>

          <div class="footnotes">
            <p>eGFR：估算肾小球滤过率；ESKD：终末期肾病</p>
            <p><span class="bold">参考文献：1.</span> KDIGO. <em>Kidney Int</em>. 2021;100:S1-S276. <span
                class="bold">2.</span> Thompson A, et al. <em>Clin J Am Soc Nephrol</em>. 2019;14(3):469-481. <span
                class="bold">3.</span> Inker L, et al. <em>Am J Kidney Dis</em>. 2016;68(3):392-401.</p>
          </div>
        </div>

        <div class="carousel-block" id="sarah-block-6">
          <h3 class="label">活检时ACE<span class="lower">i</span>/ARB使用情况</h3>
          <h4 class="characteristic">None</h4>

          <p>ACEi/ARB是指南推荐的支持治疗，但莎拉在活检时尚未启动该治疗。<sup>1</sup></p>

          <div class="footnotes">
            <p>ACEi：血管紧张素转换酶抑制剂；ARB：血管紧张素 Ⅱ 受体拮抗剂</p>
            <p><span class="bold">参考文献：1.</span> KDIGO. <em>Kidney Int</em>. 2021;100:S1-S276.</p>
          </div>
        </div>

        <div class="carousel-block" id="sarah-block-7">
          <h3 class="label">MEST-C 评分</h3>
          <h4 class="characteristic">M1 E0 S0 T0 C0</h4>

          <p>莎拉的活检采用牛津分型（即 MEST-C 评分 ）进行评估。活检显示，其超过 50% 的肾小球存在系膜细胞增生，但无毛细血管内皮细胞增生、节段性肾小球硬化、肾小管萎缩/间质纤维化及新月体形成。</p>
          <p>MEST-C 评分可作为具有价值的早期预后评估工具，在评估疾病进展至ESKD的风险时，应将其纳入考量。<sup>1-3</sup></p>

          <div class="button cta modal-trigger" data-trigger-id="mest-c-score">
            <p>了解更多关于 MEST-C 的信息</p>
          </div>

          <div class="footnotes">
            <p>ESKD：终末期肾病；MEST-C：系膜细胞增生（M）、毛细血管内皮细胞增生（E）、节段性硬化（S）、肾小管萎缩和间质纤维化（T）、新月体（C）；</p>
            <p><span class="bold">参考文献：1.</span> Cattran DC, et al. <em>Kidney Int Rep</em>.
              2023;8(12):2515-2528. <span class="bold">2.</span> Haaskjold YL, et al. <em>BMC Nephrology</em>.
              2022;23:26. <span class="bold">3.</span> Coppo R, et al. <em>Kidney Int</em>. 2014;86(4):828-836.</p>
          </div>
        </div>

        <div class="carousel-block" id="sarah-block-8">
          <h3 class="label">活检时或活检前免疫抑制剂使用情况</h3>
          <h4 class="characteristic">未使用</h4>

          <p>免疫抑制治疗对IgA肾病患者的临床获益尚未明确，<br>
            经评估风险与获益可接受时，<br>
            特定患者人群可考虑采用。<sup>1</sup></p>

          <div class="footnotes">
            <p><span class="bold">参考文献：1.</span> KDIGO. <em>Kidney Int</em>. 2021;100:S1-S276.</p>
          </div>
        </div>
      </div>
    </section>
    
    <div class="temp-section">
      <div class="footnotes">
        <p>*图片经 Renal Fellow Network授权使用，来源：Gallan A. Kidney biopsy of the Month. 2019年7月29日在线发表，可在此处查看: Kidney Biopsy of the Month: IgA Nephropathy - Renal Fellow Network/。</p>
        <p>ACE：血管紧张素转换酶；ARB：血管紧张素II受体阻滞剂；eGFR：估算肾小球滤过率；HPF：高倍视野；MEST-C：系膜细胞增生（M）、毛细血管内皮细胞增生（E）、节段性硬化（S）、肾小管萎缩和间质纤维化（T）、新月体（C）；PAS：过碘酸-希夫（染色法）；RBC：红细胞；UPCR，尿蛋白肌酐比值。</p>
      </div>

      <img class="mobile-only update-path mobile-bio-trigger" data-tray-id="sarah-bio-tray" id="mobile-bio-trigger" src="./assets/images/profiles/mobile-bio-btn.png" alt="Baseline Assessment trigger button"/>
    </div>

    <!-- //////////////////// SECTION 3 ///////////////////// -->

    <section id="section-3" class="gray-bg" data-section-id="3" data-section-name="Sarah's Risk of Progression" data-dot-label="疾病进展风险">
      <div class="flex-header">
        <img src="./assets/images/profiles/sarah-profile.png" class="update-path bio-pic desktop-only" alt="">

        <div>
          <h1 class="pat-header">莎拉的疾病进展风险</h1>
          <p class="desc-text">莎拉的IgA肾病经活检确诊后，医生为其开具了ACEi/ARB。<br>
          一年后，通过支持治疗和调整生活方式，<br>
          她的蛋白尿稳定在 1 g/d，血压降至 120/80 mm Hg </p>

          <div class="graph-container">
            <div class="hotspot" id="state-1" data-value="Age 27;5%"></div>
            <div class="hotspot" id="state-2" data-value="Age 28;11%"></div>
            <div class="hotspot" id="state-3" data-value="Age 29;18%"></div>
            <div class="hotspot" id="state-4" data-value="Age 30;25%"></div>
            <div class="hotspot" id="state-5" data-value="Age 31;33%"></div>

            <div class="tablet-desktop-only">
              <img src="./assets/images/profiles/sarah/progression-graph-state-0.png" id="state-0"
                class="graph update-path"
                alt="Graph showing Sarah's risk of progression one year after stabilization on optimized supportive care" />
              <img src="./assets/images/profiles/sarah/progression-graph-state-1.png" id="state-1"
                class="graph visible update-path"
                alt="Graph showing Sarah's risk of progression at age 27. 5 percent risk one year after stabilization on optimized supportive care" />
              <img src="./assets/images/profiles/sarah/progression-graph-state-2.png" id="state-2"
                class="graph update-path"
                alt="Graph showing Sarah's risk of progression at age 28. 11 percent risk two years after stabilization on optimized supportive care" />
              <img src="./assets/images/profiles/sarah/progression-graph-state-3.png" id="state-3"
                class="graph update-path"
                alt="Graph showing Sarah's risk of progression at age 29. 18 percent risk three years after stabilization on optimized supportive care" />
              <img src="./assets/images/profiles/sarah/progression-graph-state-4.png" id="state-4"
                class="graph update-path"
                alt="Graph showing Sarah's risk of progression at age 30. 25 percent risk four years after stabilization on optimized supportive care" />
              <img src="./assets/images/profiles/sarah/progression-graph-state-5.png" id="state-5"
                class="graph update-path"
                alt="Graph showing Sarah's risk of progression at age 31. 33 percent risk five years after stabilization on optimized supportive care" />
            </div>

            <div class="mobile-only">
              <img src="./assets/images/profiles/sarah/mobile/progression-graph-state-0-mobile.png" id="state-0"
              class="graph mobile-graph update-path"
              alt="Graph showing Sarah's risk of progression one year after stabilization on optimized supportive care" />
              <img src="./assets/images/profiles/sarah/mobile/progression-graph-state-1-mobile.png" id="state-1"
              class="graph mobile-graph visible update-path"
              alt="Graph showing Sarah's risk of progression at age 27. 5 percent risk one year after stabilization on optimized supportive care" />
              <img src="./assets/images/profiles/sarah/mobile/progression-graph-state-2-mobile.png" id="state-2"
              class="graph mobile-graph update-path"
              alt="Graph showing Sarah's risk of progression at age 28. 11 percent risk two years after stabilization on optimized supportive care" />
              <img src="./assets/images/profiles/sarah/mobile/progression-graph-state-3-mobile.png" id="state-3"
              class="graph mobile-graph update-path"
              alt="Graph showing Sarah's risk of progression at age 29. 18 percent risk three years after stabilization on optimized supportive care" />
              <img src="./assets/images/profiles/sarah/mobile/progression-graph-state-4-mobile.png" id="state-4"
              class="graph mobile-graph update-path"
              alt="Graph showing Sarah's risk of progression at age 30. 25 percent risk four years after stabilization on optimized supportive care" />
              <img src="./assets/images/profiles/sarah/mobile/progression-graph-state-5-mobile.png" id="state-5"
              class="graph mobile-graph update-path"
              alt="Graph showing Sarah's risk of progression at age 31. 33 percent risk five years after stabilization on optimized supportive care" />
            </div>
          </div>

          <a href="https://qxmd.com/calculate/calculator_499/international-igan-prediction-tool-at-biopsy-adults"
          target="_blank" class="button cta" id="sect-3-exit">
          <p>查看国际 IgA肾病预测工具</p>
          <img src="./assets/images/external-icon-white.svg" class="update-path" alt="External link icon" />
        </a>

        </div>
      </div>

      <p class="bold">当前KDIGO指南不建议在非糖尿病的IgA肾病患者中使用SGLT2i ，因其疗效和安全性数据还有待完善。<br>
        虚拟患者病例采用的治疗依据当前治疗指南制定。<sup>2</sup></p>

      <div class="footnotes">
        <p><sup>a</sup>疾病进展风险通过国际IgA肾病预测工具计算，定义为 eGFR 下降 50% 或发生 ESKD 的风险<sup>1</sup></p>
        <p>ACEi：血管紧张素转换酶抑制剂；ARB：血管紧张素II受体阻滞剂；eGFR：估算肾小球滤过率；<br>
        ESKD：终末期肾病；KDIGO：改善全球肾脏病预后组织；SGLT2i：钠-葡萄糖协同转运蛋白 2 抑制剂。</p>
        <p><span class="bold">参考文献: 1.</span> Barbour SJ, et al. <em>Kidney Int</em>. 2022;102(1):160-172. <span
            class="bold">2.</span> KDIGO. <em>Kidney Int</em>. 2021;100:S1-S276.</p>
      </div>

    </section>

    <!-- //////////////////// SECTION 4 ///////////////////// -->

    <section id="section-4" class="" data-section-id="4" data-section-name="Sarah Impact of Proteinuria" data-dot-label="蛋白尿的影响">
      <div class="flex-header">
        <img src="./assets/images/profiles/sarah-profile.png" class="update-path bio-pic desktop-only" alt="">

        <div>
          <h1 class="pat-header">蛋白尿的影响</h1>
          <p class="desc-text">尽管莎拉的蛋白尿水平减半至 1 g/d，<br>
          但她仍存在疾病进展风险。</p>
        </div>
      </div>

      <div class="flex">
        <div class="text-side">
          <p class="bold">一项回顾性队列研究显示，<br>
            低风险的患者仍存在 10 年内<br>
            进展为 ESKD 的风险<sup>2</sup></p>

          <ul class="bullet-list">
            <li><span class="bullet">&bull;</span><span>蛋白尿为 0.5 至 1 g/d的患者，风险为 30%</span></li>
            <li><span class="bullet">&bull;</span><span>蛋白尿＜0.5 g/d的患者，风险约为 20%</span></li>
          </ul>
        </div>

        <div class="right-side">
          <p class="bold purple">滑动查看将蛋白尿降至 1 g/d 以下，<br>
            如何降低莎拉的疾病进展风险。</p>
          
          <div class="flex">
            <img src="./assets/images/profiles/sarah/risk-23.png" id="section-4-state-1" class="risk-radial update-path"
              alt="23 percent risk progression at 5 years with proteinuria at 0.5 g/d" />
            <img src="./assets/images/profiles/sarah/risk-28.png" id="section-4-state-2" class="risk-radial update-path"
              alt="28 percent risk progression at 5 years with proteinuria at 0.75 g/d" />
            <img src="./assets/images/profiles/sarah/risk-33.png" id="section-4-state-3"
              class="risk-radial update-path visible" alt="33 percent risk progression at 5 years with proteinuria at 1 g/d" />
    
            <div class="slider-container">
              <div id="state-1-blurb">
                <p>Reducing proteinuria from 1 g/d to 0.5 g/d lowers the risk of progression by ~10%</p>
              </div>
              <div class="">
                <img src="./assets/images/profiles/sarah/section-4-slider-1.svg" id="section-4-state-1"
                  class="slider update-path" alt="Slider shown at 0.5 g/d" />
                <img src="./assets/images/profiles/sarah/section-4-slider-2.svg" id="section-4-state-2"
                  class="slider update-path" alt="Slider shown at 0.75 g/d" />
                <img src="./assets/images/profiles/sarah/section-4-slider-3.svg" id="section-4-state-3"
                  class="slider update-path visible" alt="Slider shown at 1.0 g/d" />
              </div>

              <div class="ff-hotspots hidden">
                <div class="hotspot" id="section-4-state-3" data-value="1.0 g/d"></div>
                <div class="hotspot" id="section-4-state-2" data-value="0.75 g/d"></div>
                <div class="hotspot" id="section-4-state-1" data-value="0.5 g/d"></div>
              </div>
      
              <input type="range" class="range-slider" id="pro-impact" orient="vertical" name="pro-impact" min="1" max="3" value="3" step="1" />
            </div>
          </div>
        </div>
      </div>

      <div class="footnotes">
        <p><sup>a</sup>疾病进展风险通过国际IgA肾病预测工具计算，定义为 eGFR 下降 50% 或发生 ESKD 的风险。</p>
        <p>eGFR：估算肾小球滤过率；ESKD：终末期肾病</p>
        <p><span class="bold">参考文献: 1.</span> Barbour SJ, et al. <em>Kidney Int</em>. 2022;102(1):160-172. <span
            class="bold">2.</span> Pitcher D, et al. <em>Clin J Am Soc Nephrol</em>. 2023;18(6):727-738.</p>
      </div>
    </section>

    <!-- //////////////////// SECTION 5 ///////////////////// -->

    <section id="section-5" class="" data-section-id="5" data-section-name="Sarah Changes in Proteinuria and eGFR Over Time" data-dot-label="eGFR 随时间的变化">
      <div class="flex-header">
        <img src="./assets/images/profiles/sarah-profile.png" class="update-path bio-pic desktop-only" alt="">

        <div>
          <h1 class="pat-header">蛋白尿与 eGFR <br/>
            随时间的变化</h1>
          <p class="desc-text">通过药物治疗和生活方式调整，莎拉能够降低蛋白尿水平，<br>并延缓 eGFR 的下降。</p>
        </div>
      </div>

      <p class="graphs-header">蛋白尿与 eGFR 随时间的变化</p>
      <p class="direction">滑动查看莎拉的蛋白尿和 eGFR 随时间的变化</p>

      <img src="./assets/images/profiles/sarah/section-5-key.png" class="update-path key tablet-desktop-only" alt=""/>

      <div class="graphs-container">
        <div class="left-side">
          <div class="tablet-desktop-only">
            <img src="./assets/images/profiles/sarah/pro-over-time-state-1.png" id="section-5-state-1"
              class="update-path graph visible" alt="Graph modeling proteinuria progression over time with and without intervention, starting at biopsy"/>
            <img src="./assets/images/profiles/sarah/pro-over-time-state-2.png" id="section-5-state-2"
              class="update-path graph" alt="Graph showing proteinuria level with and without intervention, after two years"/>
            <img src="./assets/images/profiles/sarah/pro-over-time-state-3.png" id="section-5-state-3"
              class="update-path graph" alt="Graph showing proteinuria progression with and without intervention, at four years"/>
            <img src="./assets/images/profiles/sarah/pro-over-time-state-4.png" id="section-5-state-4"
              class="update-path graph" alt="Graph showing proteinuria with and without intervention, at six years"/>
          </div>
          <div class="mobile-only">
            <img src="./assets/images/profiles/sarah/mobile/pro-over-time-state-1-mobile.png" id="section-5-state-1"
              class="update-path mobile-graph graph visible" alt="Graph modeling proteinuria progression over time with and without intervention, starting at biopsy"/>
            <img src="./assets/images/profiles/sarah/mobile/pro-over-time-state-2-mobile.png" id="section-5-state-2"
              class="update-path mobile-graph graph" alt="Graph showing proteinuria level with and without intervention, after two years"/>
            <img src="./assets/images/profiles/sarah/mobile/pro-over-time-state-3-mobile.png" id="section-5-state-3"
              class="update-path mobile-graph graph" alt="Graph showing proteinuria progression with and without intervention, at four years"/>
            <img src="./assets/images/profiles/sarah/mobile/pro-over-time-state-4-mobile.png" id="section-5-state-4"
              class="update-path mobile-graph graph" alt="Graph showing proteinuria with and without intervention, at six years"/>
          </div>
        </div>
        <div class="right-side">
          <div class="tablet-desktop-only">
            <img src="./assets/images/profiles/sarah/egfr-over-time-state-1.png" id="section-5-state-1"
              class="update-path graph visible" alt="Graph modeling eGFR decline over time with and without intervention, starting at biopsy"/>
            <img src="./assets/images/profiles/sarah/egfr-over-time-state-2.png" id="section-5-state-2"
              class="update-path graph" alt="Graph showing eGFR with and without intervention, after two years"/>
            <img src="./assets/images/profiles/sarah/egfr-over-time-state-3.png" id="section-5-state-3"
              class="update-path graph" alt="Graph showing eGFR with and without intervention, after four years"/>
            <img src="./assets/images/profiles/sarah/egfr-over-time-state-4.png" id="section-5-state-4"
              class="update-path graph" alt="Graph showing eGFR with and without intervention, after six years"/>
            </div>
            <div class="mobile-only">
              <img src="./assets/images/profiles/sarah/mobile/egfr-over-time-state-1-mobile.png" id="section-5-state-1"
                class="update-path mobile-graph graph visible" alt="Graph modeling eGFR decline over time with and without intervention, starting at biopsy"/>
              <img src="./assets/images/profiles/sarah/mobile/egfr-over-time-state-2-mobile.png" id="section-5-state-2"
                class="update-path mobile-graph graph" alt="Graph showing eGFR with and without intervention, after two years"/>
              <img src="./assets/images/profiles/sarah/mobile/egfr-over-time-state-3-mobile.png" id="section-5-state-3"
                class="update-path mobile-graph graph" alt="Graph showing eGFR with and without intervention, after four years"/>
              <img src="./assets/images/profiles/sarah/mobile/egfr-over-time-state-4-mobile.png" id="section-5-state-4"
                class="update-path mobile-graph graph" alt="Graph showing eGFR with and without intervention, after six years"/>
          </div>
        </div>
      </div>

      <div class="slider-container">
        <div class="tablet-desktop-only">
          <img src="./assets/images/profiles/over-time-slider-1.svg" id="section-5-state-1" class="update-path slider visible" 
            alt="Slider shown at biopsy stage">
          <img src="./assets/images/profiles/over-time-slider-2.svg" id="section-5-state-2" class="update-path slider"
            alt="Slider shown at 2 years">
          <img src="./assets/images/profiles/over-time-slider-3.svg" id="section-5-state-3" class="update-path slider"
            alt="Slider shown at 4 years">
          <img src="./assets/images/profiles/over-time-slider-4.svg" id="section-5-state-4" class="update-path slider"
            alt="Slider shown at 6 years">
        </div>
        <div class="mobile-only">
          <img src="./assets/images/profiles/over-time-slider-1-mobile.png" id="section-5-state-1"
            class="update-path mobile-graph slider visible" alt="Slider shown at biopsy stage">
          <img src="./assets/images/profiles/over-time-slider-2-mobile.png" id="section-5-state-2" class="update-path mobile-graph slider"
            alt="Slider shown at 2 years">
          <img src="./assets/images/profiles/over-time-slider-3-mobile.png" id="section-5-state-3" class="update-path mobile-graph slider"
            alt="Slider shown at 4 years">
          <img src="./assets/images/profiles/over-time-slider-4-mobile.png" id="section-5-state-4" class="update-path mobile-graph slider"
            alt="Slider shown at 6 years">
        </div>

        <input type="range" class="range-slider" id="changes-over-time" name="changes-over-time" min="1" max="4" value="1" step="1" />
      </div>

      <div class="footnotes">
        <p>蛋白尿和 eGFR 的变化为基于临床试验和队列研究结果趋势的假设<sup>1-4</sup></p>
        <p>eGFR：估算肾小球滤过率。</p>
        <p><span class="bold">参考文献: 1.</span> Pitcher D, et al. <em>Clin J Am Soc Nephrol</em>.
          2023;18(6):727-738. <span class="bold">2.</span> Faucon AL, et al. <em>Nephrol Dial Transplant</em>.
          2024;30:gfae085. <span class="bold">3.</span> Rovin BH, et al. <em>Lancet</em>. 2023;402(10417):2077-2090. <span class="bold">4.</span>
          Lafayette R, et al. <em>Lancet</em>. 2023;402:859-870.</p>
      </div>
    </section>

    <!-- //////////////////// SECTION 6 ///////////////////// -->

    <section id="section-6" class="gray-bg" data-section-id="6" data-section-name="Sarah Impact of eGFR Decline on Progression to ESKD" data-dot-label="eGFR 下降对疾病进展的影响">
      <div class="flex-header">
        <img src="./assets/images/profiles/sarah-profile.png" class="update-path bio-pic desktop-only" alt="">

        <div>
          <h1 class="pat-header">eGFR 下降对疾病进展<br>
            至肾衰竭的影响</h1>
        </div>
      </div>

      <p class="graphs-header">若莎拉的 eGFR 下降情况趋于稳定，则可延缓肾衰竭的发生。</p>
      <p class="direction">选择下方按钮，查看不同的 eGFR 下降速率对进展至肾衰竭的影响。</p>

      <div class="graph-container">
        <div class="tablet-desktop-only">
          <img src="./assets/images/profiles/sarah/section-6-graph-state-0.png" id="0" class="update-path graph"
            alt="Graph depicting changes in eGFR over time" />
          <img src="./assets/images/profiles/sarah/section-6-graph-state-1.png" id="state-1" class="update-path graph"
            alt="Graph depicting changes in eGFR over time at a loss of 2 mL/min/1.73 m2 per year" />
          <img src="./assets/images/profiles/sarah/section-6-graph-state-2.png" id="state-2" class="update-path graph"
            alt="Graph depicting changes in eGFR over time at a loss of 3 mL/min/1.73 m2 per year" />
          <img src="./assets/images/profiles/sarah/section-6-graph-state-3.png" id="state-3" class="visible update-path graph"
            alt="Graph depicting changes in eGFR over time at a loss of 5 mL/min/1.73 m2 per year" />
          </div>
          <div class="mobile-only">
            <img src="./assets/images/profiles/sarah/mobile/section-6-graph-state-0-mobile.png" id="0" class="update-path mobile-graph graph"
              alt="Graph depicting changes in eGFR over time" />
            <img src="./assets/images/profiles/sarah/mobile/section-6-graph-state-1-mobile.png" id="state-3" class="visible update-path mobile-graph graph"
              alt="Graph depicting changes in eGFR over time at a loss of 2 mL/min/1.73 m2 per year" />
            <img src="./assets/images/profiles/sarah/mobile/section-6-graph-state-2-mobile.png" id="state-2" class="update-path mobile-graph graph"
              alt="Graph depicting changes in eGFR over time at a loss of 3 mL/min/1.73 m2 per year" />
            <img src="./assets/images/profiles/sarah/mobile/section-6-graph-state-3-mobile.png" id="state-1" class="update-path mobile-graph graph"
              alt="Graph depicting changes in eGFR over time at a loss of 5 mL/min/1.73 m2 per year" />
        </div>

        <div class="hotspot" id="state-1" data-value="Annual eGFR loss: -2 mL/min/1.73 m^2/year"></div>
        <div class="hotspot" id="state-2" data-value="Annual eGFR loss: -3 mL/min/1.73 m^2/year"></div>
        <div class="hotspot" id="state-3" data-value="Annual eGFR loss: -5 mL/min/1.73 m^2/year"></div>

        <div class="upper-hotspots">
          <div class="hotspot lower-hotspot" id="state-3" data-value="Annual eGFR loss: -5 mL/min/1.73 m^2/year"></div>
          <div class="hotspot lower-hotspot" id="state-2" data-value="Annual eGFR loss: -3 mL/min/1.73 m^2/year"></div>
          <div class="hotspot lower-hotspot" id="state-1" data-value="Annual eGFR loss: -2 mL/min/1.73 m^2/year"></div>
        </div>
      </div>

      <div class="footnotes">
        <p>CKD：慢性肾脏病；eGFR：估算肾小球滤过率。</p>
      </div>
    </section>

    <!-- //////////////////// SECTION 7 ///////////////////// -->

    <section id="section-7" class="gray-bg" data-section-id="7" data-section-name="Sarah Considerable Impact on Physical, Mental, and Emotional Health" data-dot-label="QoL 的影响">
      <div class="flex-header">
        <img src="./assets/images/profiles/sarah-profile.png" class="update-path bio-pic desktop-only" alt="">

        <div>
          <h1 class="pat-header">对身体、心理及情绪健康的显著影响<sup>1,2</sup></h1>
        </div>
      </div>

      <div class="icon-flex">
        <div class="icon-container">
          <img src="./assets/images/profiles/blue-icon-anxiety.svg" class="update-path" alt="" />
          <p>约 25% 的 IgA肾病患者<br>
            存在焦虑<sup>1,a</sup></p>
        </div>
        <div class="icon-container">
          <img src="./assets/images/profiles/blue-icon-depression.svg" class="update-path" alt="" />
          <p>约 30% 的 IgA肾病患者<br>
            存在抑郁<sup>2,b</sup></p>
        </div>
        <div class="icon-container">
          <img src="./assets/images/profiles/blue-icon-activity.svg" class="update-path" alt="" />
          <p>约 40% 的患者<br>
            报告日常活动受限<sup>3,c</sup></p>
        </div>
        <div class="icon-container">
          <img src="./assets/images/profiles/blue-icon-work.svg" class="update-path" alt="" />
          <p>高达 40% 的患者<br>
            存在整体工作能力受限<sup>3,c</sup></p>
        </div>
      </div>

      <div class="footnotes">
        <p class=""><sup>a</sup>基于 NKF 患者之声报告 ，美国 IgA肾病患者应对情况的调查。</p>
        <p class=""><sup>b</sup>对经活检确诊为 IgA肾病的成年患者开展的前瞻性观察性研究。</p>
        <p class=""><sup>c</sup>基于阿德菲 IgA肾病疾病特定项目（DSP）的真实世界数据，该项目是 2021 年 6 月至 10 月期间，针对美国、欧盟五国（法国、德国、意大利、西班牙和英国 ）、日本及中国的主治 IgA肾病的肾病科医生及其患者开展的时点调查。所呈现数据为美国 IgA肾病患者的数据，且基于参与者报告的平均损害情况</p>

        <p><span class="bold">参考文献: 1.</span> The Voice of the Patient. National Kidney Foundation. December 8,
          2020. Accessed June 10, 2024. https://www.igan.org/wp-content/uploads/2021/01/VOP_IgAN_12-7-20__FNL.pdf. <span
            class="bold">2.</span> Zhao Y, et al. <em>J Int Med Res</em>. 2020;48(1):300060519898008. <span
            class="bold">3.</span> Lafayette R, et al. Poster. International Symposium on IgA Nephropathy; Tokyo, Japan.
          September 28-30, 2023 (poster P-51).</p>
      </div>
    </section>

    <section class="switch-pat-section" id="switch-pat" data-section-name="Switch Patient">
      <h2 class="yellow-header">选择另一名虚拟患者</h2>

      <div class="flex">
        <div class="profile nav-el" data-nav-url="progression/carlos" data-exit-url="progression/carlos">
          <img src="./assets/images/profiles/carlos-profile.png" class="update-path" alt="" />
          <h3>卡洛斯</h3>
        </div>
        <div class="profile nav-el" data-nav-url="progression/mark" data-exit-url="progression/mark">
          <img src="./assets/images/profiles/mark-profile.png" class="update-path" alt="" />
          <h3>马克</h3>
        </div>
      </div>

      <img src="./assets/images/or-line-graphic.png" class="or-line update-path" alt="Or" />

      <div class="button nav-el" id="discover" data-nav-url="pathogenesis/index" data-exit-url="pathogenesis/index">
        <p>探索 IgA肾病的疾病机制</p>
      </div>
    </section>

    {{> ../templates/footer-el }}

  </main>

  <script type="text/javascript" src="../static.bundle.js" charset="utf-8"></script>
</body>

</html>